<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3669">
  <stage>Registered</stage>
  <submitdate>30/10/2012</submitdate>
  <approvaldate>30/10/2012</approvaldate>
  <nctid>NCT01720056</nctid>
  <trial_identification>
    <studytitle>Verapamil vs Steroid to Prevent Keloid Recurrence</studytitle>
    <scientifictitle>Assessment of Verapamil as an Adjunct for Prevention of Keloid Recurrence After Surgical Removal</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EC 067/2012</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Keloid Scars</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Verapamil
Treatment: drugs - Kenalog 10

Active Comparator: Verapamil - Verapamil 2.5 mg/mL injection sc intralesionally

Active Comparator: Kenalog 10 - Kenalog 10 mg/mL injection sc intralesionally


Treatment: drugs: Verapamil


Treatment: drugs: Kenalog 10


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Keloid recurrence</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Vancouver Scar Scale Score</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient undergoing surgical removal of keloid

          -  Patient 18 years old or greater

          -  Length of excisional scar after surgical removal of keloid between 2 and 10 cm</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Keloid in face or hands

          -  Pregnancy or lactation

          -  Dementia

          -  Any heart or pulmonary condition

          -  Systemic treatment with beta-blockers, ACE-inhibitors or calcium antagonists

          -  Systemic corticosteroidal therapy

          -  Intralesional steroid treatment within 2 months of surgery to remove keloid

          -  Flap surgery

          -  Lesions to face, hands and other cosmetically sensitive areas</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>14</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>6001 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of Western Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Keloid scarring is a severe cosmetic and painful disease of the skin. The gold standard
      treatment is yet to be clarified. This randomized clinical pilot study will compare the
      effects of two local treatments for preventing keloid recurrence after surgical removal;
      steroid and verapamil.

      Study hypothesis: Intralesional therapy with the calcium antagonist verapamil has equal
      treatment efficacy as steroid injection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01720056</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Fiona M Wood, Professor</name>
      <address>The University of Western Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>